Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pharmacological decongestion: from loop diuretics to sequential nephron blockade].

Giornale italiano di cardiologia (2006)·2026
Same author

[Inotropic therapy in outpatients with worsening or advanced heart failure: literature evidence and comparison of Italian management models].

Giornale italiano di cardiologia (2006)·2026
Same author

[PONTE-HF/ACS registry: optimization of medical therapy in outpatient clinics in Apulia for patients with heart failure].

Giornale italiano di cardiologia (2006)·2026
Same author

Impact of chronic kidney disease on treatment implementation and prognosis of patients with heart failure: A large retrospective observational analysis from the Italian Network-Heart Failure (IN-HF) registry.

European journal of internal medicine·2026
Same author

Hypokinetic nondilated cardiomyopathy: clinical characteristics, prognosis, and therapy response compared to dilated cardiomyopathy.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Finerenone: Extending MRAs Prognostic Benefit to the Recently Hospitalized and More Symptomatic Patient with HFpEF.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Jun 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Systemic inflammation in nonischemic dilated cardiomyopathy.

Luisa De Gennaro1, Natale Daniele Brunetti, Andrea Cuculo

  • 1Cardiology Department, University of Foggia, viale L. Pinto 1, 71100 Foggia, Italy.

Heart and Vessels
|November 28, 2008
PubMed
Summary

Systemic inflammation is linked to nonischemic dilated cardiomyopathy (NIDC) severity. Inflammatory markers like C-reactive protein (CRP) correlate with poorer heart function and symptoms, suggesting inflammation impacts NIDC progression.

More Related Videos

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

Related Experiment Videos

Last Updated: Jun 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

Area of Science:

  • Cardiology
  • Immunology
  • Internal Medicine

Background:

  • Nonischemic dilated cardiomyopathy (NIDC) is a complex heart condition.
  • The role of systemic inflammation in NIDC progression is not fully understood.

Purpose of the Study:

  • To investigate the association between systemic inflammatory markers and the clinical presentation of NIDC.
  • To determine if inflammation correlates with disease severity and cardiac function in NIDC patients.

Main Methods:

  • Study included 31 NIDC patients, excluding those with other heart or systemic diseases.
  • Evaluated clinical status (NYHA class), left ventricular ejection fraction (LVEF), and plasma inflammatory markers (CRP, ESR, fibrinogen).
  • Statistical analysis correlated inflammatory markers with NYHA class and LVEF, adjusting for confounders.

Main Results:

  • NYHA functional class significantly correlated with fibrinogen, CRP, and ESR.
  • LVEF was inversely related to fibrinogen and CRP levels.
  • Statin use was associated with lower CRP levels, and correlations remained significant after adjustments.

Conclusions:

  • Elevated inflammatory markers in NIDC are proportional to symptom severity and impaired systolic function.
  • Systemic inflammation may contribute to the deterioration of NYHA class in NIDC.
  • Inflammation is a potential factor in the pathophysiology and progression of NIDC.